VEGFA and chronic recurrent multifocal osteomyelitis: Anti-VEGF therapy such as ranibizumab and bevacizumab appear to be of little value in the management of CMO in BCR; studies of their use in CMO-associated with a range of forms of uveitis suggest that they are well-tolerated but the effect is limited and transient [93–96].